Elsevier

Basal Ganglia

Volume 5, Issues 2–3, August 2015, Pages 51-55
Basal Ganglia

The vulnerable ventral tegmental area in Parkinson’s disease

https://doi.org/10.1016/j.baga.2015.06.001Get rights and content

Highlights

  • We ran a literature review on degeneration of the VTA in PD and added new cases.

  • The literature unequivocally demonstrates that the VTA is involved in PD.

  • Our new cases support previous ones with significant degeneration in the VTA.

Abstract

Introduction

The involvement of dopaminergic neurons in the ventral tegmental area (VTA) in Parkinson’s disease (PD) has not been universally recognized by neuroscientists and neurologists. Here, we conduct a review of previous research documenting dopaminergic neuronal loss in both the substantia nigra pars compacta (SNpc) and VTA and add three new post-mortem PD cases to the literature.

Methods

PD and control brains were sectioned, stained for tyrosine hydroxylase, and cells in the SNpc and VTA were counted.

Results

Based on the review, we report two main results: (1) the VTA does degenerate in PD, and (2) the VTA degenerates less than the SNpc.

Conclusion

Inconsistent clinical information about these cases limits our ability to interpret how the VTA contributes to PD symptoms. However, our data in combination with prior PD neuropathological cases in the literature unequivocally establish that the VTA is involved in PD, and could be relevant for future investigation of non-motor symptoms in PD.

Introduction

Parkinson’s disease (PD) is a progressive neurodegenerative disorder that causes motor disabilities and cognitive dysfunction due to the degeneration and loss of dopaminergic neurons in the midbrain. There is no debate as to whether the loss of neurons in the substantia nigra pars compacta (SNpc) is directly causative of the motor symptoms of PD [1]. While the ventral tegmental area (VTA) has long been suggested to be involved in PD [2], some authors have stated that the VTA is relatively spared [3], [4], [5], [6] and some textbooks of neurology, neuroscience, and movement disorders state that the VTA is “affected little or not at all” [7], [8]. Our motivation for this study was to review the existing literature and investigate the degree to which the VTA is involved in PD.

Previous research has provided several theories explaining this relative sparing, such as the variety of neurons found in the VTA [3], [4], lower expression of the dopamine transporter [5], differences in calcium channel expression, as well as in levels of cytosolic dopamine and the presence of α-synuclein [6], [9]. Here, we conduct a review of eight previous neuropathological studies in humans that directly quantified dopamine neurons in both the SNpc and VTA and add three new PD cases to the literature. We conclude, unequivocally, that the VTA degenerates in PD. This information could be helpful in understanding the pathophysiology of non-motor symptoms of PD. This line of evidence is consistent with widespread degeneration of ascending projection systems in PD including cholinergic, noradrenergic, serotonergic, and dopaminergic nuclei [10].

The VTA extends laterally from the midline (0 mm) to 4 mm and from 4 mm caudal to the mammillary bodies to 9 mm [11]. It contains dopamine neurons that project mainly to the ventral striatum and prefrontal cortex, with some projections to the amygdala. The VTA integrates information from a variety of cortical, brainstem, and peripheral centers, and contains a diversity of dopaminergic, GABAergic, and glutamatergic neurons, while the SNpc does not express glutamatergic neurons [3], [4], [12], [13]. Due to the diversity of neurons, the VTA responds to local and distant neuromodulators [5]. The VTA has been implicated in a variety of behaviors and psychopathological states, including depression, anxiety, drug addiction, feeding, reward processing, and executive function [14]. Crucially, many PD patients have non-motor symptoms that include disorders associated with the VTA. For instance, 25% of PD patients have anxiety and/or depression [15] and nearly 30% of PD patients have executive dysfunction [16]. We present evidence from 43 previous PD cases and three new ones to explicitly test the hypothesis that the VTA is extensively involved in PD.

Section snippets

Literature review

The following key words were used to collect published journal articles on the degeneration of the VTA in PD: ventral tegmental area; Parkinson’s disease; dopamine; and degeneration. The articles were then analyzed for content of dopaminergic degeneration in the VTA and SNpc.

Collection

Seven perfusion-fixed (4% formaldehyde) human midbrains (from superior colliculus to cerebral peduncles) were collected. Brain blocks were post-fixed for at least one week in formaldehyde. For cryoprotection, midbrains were

Results

We reviewed eight studies in which TH expression was quantified in the VTA and SNpc. Though all of the previous studies reported here aimed to quantify TH differences between PD and controls, not all used the same methods. For instance, most studies used haematoxylin–eosin staining to label neuromelanin [11], [21], [22], which Bogerts had established as an appropriate marker for catecholaminergic neurons [23]. One study only characterized pigmented neurons [20], another used immunostaining for

Discussion

We report that both in previous literature and in our new data, the VTA consistently degenerates in PD. Our new cases indicate a 49 percent decrease, on average, of TH-positive cells (Table 1), which falls in the 40–77 percent range reported in previous studies [21], [26]. These data clearly and unequivocally establish that the VTA is involved in PD. We used TH as a marker of dopamine neurons; however, it should be noted that this enzyme is also found in other catecholaminergic neurons.

Acknowledgments

The authors thank the donors and their families. This study was funded by the University of Iowa Pharmacological Sciences Training Grant (5T32GM067795-11) and Dr. Narayanan’s R01 (NS089470). These funding sources did not partake in study design, data collection and analysis, or the drafting and submission of this manuscript.

References (55)

  • J.O. Rinne et al.

    Age-dependent decline in human brain dopamine D1 and D2 receptors

    Brain Res.

    (1990)
  • M.F. Salvatore et al.

    Decreased plasma membrane expression of striatal dopamine transporter in aging

    Neurobiol. Aging

    (2003)
  • H. Braak et al.

    Staging of brain pathology related to sporadic Parkinson’s disease

    Neurobiol. Aging

    (2003)
  • C.A. Davie

    A review of Parkinson’s disease

    Br. Med. Bull.

    (2008)
  • K.A. Jellinger

    Pathology of Parkinson’s disease. Changes other than the nigrostriatal pathway

    Mol. Chem. Neuropathol. Spons. Int. Soc. Neurochem. World Fed. Neurol. Res. Groups Neurochem. Cerebrospinal Fluid

    (1991)
  • E.E. Hur et al.

    Vglut2 afferents to the medial prefrontal and primary somatosensory cortices: a combined retrograde tracing in situ hybridization study [corrected]

    J. Comp. Neurol.

    (2005)
  • A.H. Ropper

    Adams and Victor’s Principles of Neurology

    (2014)
  • Marsden’s Book of Movement Disorders

  • P.-Y. Pan et al.

    Calbindin controls release probability in ventral tegmental area dopamine neurons

    Nat. Neurosci.

    (2012)
  • N.S. Narayanan et al.

    Prefrontal dopamine signaling and cognitive symptoms of Parkinson’s disease

    Rev. Neurosci.

    (2013)
  • D.C. German et al.

    Midbrain dopaminergic cell loss in Parkinson’s disease: computer visualization

    Ann. Neurol.

    (1989)
  • T. Nagai et al.

    Distribution of GABA-T-intensive neurons in the rat forebrain and midbrain

    J. Comp. Neurol.

    (1983)
  • S.M. Williams et al.

    Widespread origin of the primate mesofrontal dopamine system

    Cereb. Cortex

    (1998)
  • D. Aarsland et al.

    Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis

    Neurology

    (2010)
  • E. Elgh et al.

    Cognitive function in early Parkinsonös disease: a population-based study

    Eur. J. Neurol. Off. J. Eur. Fed. Neurol. Soc.

    (2009)
  • J.A. Feekes et al.

    The vascular supply of the functional compartments of the human striatum

    Brain

    (2006)
  • G.R. Uhl et al.

    Parkinson’s disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions

    Neurology

    (1985)
  • Cited by (112)

    View all citing articles on Scopus
    View full text